Synopsis of recent research by authors named "Keiju Aokage"
- Keiju Aokage's recent research primarily focuses on the treatment and prognosis of non-small cell lung cancer (NSCLC), exploring innovative therapies such as the combination of immune checkpoint inhibitors and angiogenesis inhibitors, as well as the implications of surgical interventions in advanced cases.
- Aokage has conducted various clinical trials and studies examining the efficacy and safety of neoadjuvant therapies, including pembrolizumab and ramucirumab, and assessed the impact of tumor microenvironmental factors on patient outcomes, particularly in relation to locoregional relapse and tumor characteristics.
- Additionally, his work investigates the prognostic significance of specific histopathological features and grading systems in lung cancer, utilizing advanced methodologies such as machine learning to enhance the understanding and management of lung cancer.
